Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension (PAH)

In brief

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Key facts

Study ID
NCT07318597
Run by
Regeneron Pharmaceuticals
People needed
99
Starts
2026-05-06
Expected to finish
2028-09-17
Last updated by the study team
2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.